COMMUNIQUÉS West-GlobeNewswire

Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate Highlights
31/07/2024
COVALENT-111 Phase 2b on track for Q4 2024 readout COVALENT-112 Phase 2a on track for Q4 2024 readout Announcement of the third program in obesity on track for Q3 2024 REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE [...]
Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024
31/07/2024
REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced [...]
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
31/07/2024
- IMM-1-104 Fast Track designation now granted for the treatment of both first and second-line pancreatic ductal adenocarcinoma (PDAC); provides potential to accelerate IMM-1-104’s path to U.S. FDA submission for PDAC [...]
Elutia Appoints Ryan Marques, Ph.D., MBA as Vice President of Operations
31/07/2024
SILVER SPRING, Md., July 31, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced the appointment of Ryan Marques, Ph.D, MBA as Vice President of [...]
Psyence Biomed Enters Into $25 Million Common Stock Purchase Agreement with White Lion Capital, LLC
31/07/2024
NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it has entered into a $25 million common stock purchase agreement (the “Purchase [...]
AVITA Medical Expands Portfolio with Unique Dermal Matrix to Advance Wound Care
31/07/2024
Exclusive development and distribution agreement with Regenity Biosciences provides AVITA Medical with the commercialization rights to a unique collagen-based dermal matrix following 510(k) clearance VALENCIA, Calif., [...]
Avadel Pharmaceuticals Announces First Patient Dosed in Phase 3 REVITALYZ™ Trial of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia
31/07/2024
DUBLIN, July 31, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that the first patient has been [...]
MIMEDX Announces Launch of HELIOGEN™ Fibrillar Collagen Matrix
31/07/2024
Limited market release marks first xenograft addition to Company’s portfolio of leading Wound and Surgical products MARIETTA, Ga., July 31, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “ [...]
Standard BioTools Announces Senior Leadership Changes
31/07/2024
Alex Kim, Chief Operating Officer and Standard BioTools Co-Founder, to Serve as interim Chief Financial Officer Following Departure of Jeffrey Black on August 31, 2024 Industry Veteran Sean Mackay Named Chief Business [...]
Bionano to Present at the Canaccord Genuity 44th Annual Growth Conference
31/07/2024
SAN DIEGO, July 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present at the Canaccord Genuity 44 th [...]
MIMEDX Announces Second Quarter 2024 Operating and Financial Results
31/07/2024
Net Sales of $87 Million Grew 7% Year-Over-Year for the Second Quarter Second Quarter GAAP Net Income and Earnings Per Share were $18 Million and $0.12 , Respectively Second Quarter Adjusted EBITDA was $20 Million, or [...]
ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer
31/07/2024
Evorpacept is the first CD47 blocker to show durable clinical benefit and a well-tolerated safety profile in a prospective randomized trial Evorpacept combination achieved a confirmed overall response rate (ORR) of 40.3 [...]
PDS Biotech to Host Clinical Program Update Conference Call on August 1, 2024, at 8 a.m. Eastern Time
31/07/2024
PRINCETON, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets [...]
Standard BioTools Reports Second Quarter 2024 Financial Results
31/07/2024
Delivered revenue of $37.2 million Accelerated merger synergies with $80 million expected to be operationalized in 2024 Revised FY2024 revenue guidance; on-track to achieve anticipated break-even adjusted EBITDA for [...]
Inventiva Reports Preliminary 2024 First-Half Financial Information¹
31/07/2024
Cash and cash equivalents at €10.1 million as of June 30, 2024, compared to cash and cash equivalents at €26.9 million, €0.01 2 million of short-term deposits and €9.0 3 million of long-term deposits as of December 31, [...]
Inventiva publie ses informations financières préliminaires du premier semestre 2024¹
31/07/2024
Trésorerie et équivalents de trésorerie à 10,1 millions d’euros au 30 juin 2024, contre 26,9 millions d’euros, 0,01 2 million d’euros de dépôts à court terme et 9,0 3 millions d’euros de dépôts à long terme au 31 [...]
GLUCOTRACK ANNOUNCES NEW FUNDING FOR DEVELOPMENT OF ITS CONTINUOUS BLOOD GLUCOSE MONITOR
31/07/2024
Rutherford, NJ, July 31, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel [...]
HilleVax Announces Reduction in Force
31/07/2024
BOSTON, July 31, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced a workforce reduction to [...]
Eurobio Scientific: CONCLUSION D’UN ACCORD ENTRE EUROBIO SCIENTIFIC ET UN CONSORTIUM MENÉ PAR L’ÉQUIPE D’ENTREPRENEURS ET DIRIGEANTS D’EUROBIO SCIENTIFIC, IK PARTNERS ET NEXTSTAGE AM EN VUE DU DÉPÔT D’UNE OFFRE PUBLIQUE D’ACHAT VOLONTAIRE A
31/07/2024
NE PAS DISTRIBUER, PUBLIER OU DIFFUSER, EN TOUT OU EN PARTIE, DIRECTEMENT OU INDIRECTEMENT, AUX ETATS-UNIS OU A TOUTE PERSONNE DES ETATS-UNIS, OU DANS TOUTE AUTRE JURIDICTION DANS LAQUELLE LA DISTRIBUTION, LA [...]

Pages